Cel-Sci Corp (CVM)

$9.16 +0.17 (1.89%)
Market Cap 61.87M
Revenue (ttm) 0.00
Net Income (ttm) -26.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,300
Avg Vol 183,810
Day's Range N/A - N/A
Shares Out 6.88M
Stochastic %K 38%
Beta 0.52
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
cruiser24
cruiser24 Oct. 25 at 10:04 PM
@BioAmerica $CVM BULLISH You talk as one of those that would love for our country to be taken over by government and corrupt agencies. Just remove all the competition in the market. Allow big pharma to control all medicines and tell us they can manufacture monopolized medicine and push down our throats they can’t be held accountable for any health issues for the next 75 years. Do away with the little guy. Sell the small farms to China. Who are the owners of the chemotherapy and radiation sells and post surgery medicines for these patients and possibly future patients of different kinds of cancer. I would say you were naive but I don’t think that is the case in listening to your investing strategy in CVM. I think you are just like the FDA and big pharma, not thinking of life or quality life for those future patients of head and neck cancer and your bragging about being on numberous other boards like this one those sicknesses either. Just like I said Money Rules even over life.
0 · Reply
MrAJax
MrAJax Oct. 25 at 6:47 PM
$CVM Geert & Saudi Arabia you are on the clock!!!! Time is running out this 60 day kicked can, will only go so far.
0 · Reply
cruiser24
cruiser24 Oct. 25 at 6:20 PM
@BioAmerica $CVM BULLISH WELL you keep posting to me expect an answer. You seem to pretend to have a problem and I’ve told you how to handle it. But NOOO you prefer to be cantankerous and act like you are some kind of boss. You might talk to your husband with a dog whistle but you are whistling in the wind here. GLTA-BULLS POAY-bears Just another day closer.
0 · Reply
BioAmerica
BioAmerica Oct. 25 at 4:24 PM
$CVM Had a little time this morning, and had a discussion with a long who has only been around a couple years. He asked me where I get all the information about all the past deals with the company. He was very interested in the 2014-2018 time frame. I found this old link to the an old annual report. It tries to explain the HALT of the trial: https://www.sec.gov/Archives/edgar/data/725363/000165495417003711/cvm_ars.pdf Start on about page 4. It explains a lot, for those who were not around back then. If have more time, you can go to the below site and read the annual reports for the next couple years. You might see an interesting change as each year goes on. https://www.annualreports.com/Company/cel-sci-corp You might have to click on "Show 10 older reports" to get to the 2017, 2018, 2019 reports. Some interesting stuff in there.
1 · Reply
cruiser24
cruiser24 Oct. 25 at 2:54 PM
$CVM BULLISH Had to take a bathroom break. That prune juice is really working. Get up out of there BG and get to work. GLTA-BULLS POAY-bears
0 · Reply
cruiser24
cruiser24 Oct. 25 at 2:44 PM
$CVM BULLISH Rich. Very rich. You make a post to @cruiser24 and then get your panties in a wad acting offended because you are answered by me. I reported you as well. Don’t start no crap won’t be no crap. Take your meds. GLTA-BULLS POAY-bears Block me and quit posting me dufus.
1 · Reply
cruiser24
cruiser24 Oct. 25 at 11:29 AM
$CVM BULLISH You won’t get any argument here. I concur. You are definitely the Spam Champion of the World. Did you get a big ole belt when you won? GLTA-BULLS POAY-bears Another day closer.
0 · Reply
prophet777
prophet777 Oct. 25 at 9:24 AM
$CVM hey what happened to our immxbiopharma/you seem angry boy… he was amusing…
0 · Reply
cruiser24
cruiser24 Oct. 24 at 10:13 PM
$CVM BULLISH Standards huh? SMH So who is the moderators of this board?
0 · Reply
cruiser24
cruiser24 Oct. 24 at 7:06 PM
$CVM News can present itself any day stocks are trading M-F. I changed my portrait so I could talk to BioGLoveMe face to face . GLTA-BULLS POAY-bears Any time now.
0 · Reply
Latest News on CVM
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 20, 2025, 9:00 AM EDT - 5 days ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Oct 10, 2025, 8:00 AM EDT - 15 days ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 29, 2025, 12:52 PM EDT - 2 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 2 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Announces Proposed Public Offering

Aug 27, 2025, 5:25 PM EDT - 2 months ago

CEL-SCI Announces Proposed Public Offering

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 14, 2025, 10:45 AM EDT - 2 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Aug 13, 2025, 9:15 AM EDT - 2 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 14, 2025, 4:05 PM EDT - 3 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 3 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jul 11, 2025, 9:15 AM EDT - 3 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

Jun 18, 2025, 9:00 AM EDT - 4 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 5 months ago

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 5 months ago

CEL-SCI Announces Pricing of Public Offering

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025, 8:00 AM EDT - 5 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 5 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 5 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 23, 2025, 8:30 AM EDT - 6 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Apr 8, 2025, 9:51 AM EDT - 7 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 24, 2025, 9:00 AM EDT - 7 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 7 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 7 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 17, 2025, 8:00 AM EDT - 7 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Mar 14, 2025, 8:30 AM EDT - 8 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 8 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Feb 18, 2025, 8:30 AM EST - 8 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Jan 14, 2025, 9:00 AM EST - 10 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 10 months ago

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 10 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 10 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Dec 12, 2024, 9:15 AM EST - 11 months ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

Nov 8, 2024, 8:00 AM EST - 1 year ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 19, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders

cruiser24
cruiser24 Oct. 25 at 10:04 PM
@BioAmerica $CVM BULLISH You talk as one of those that would love for our country to be taken over by government and corrupt agencies. Just remove all the competition in the market. Allow big pharma to control all medicines and tell us they can manufacture monopolized medicine and push down our throats they can’t be held accountable for any health issues for the next 75 years. Do away with the little guy. Sell the small farms to China. Who are the owners of the chemotherapy and radiation sells and post surgery medicines for these patients and possibly future patients of different kinds of cancer. I would say you were naive but I don’t think that is the case in listening to your investing strategy in CVM. I think you are just like the FDA and big pharma, not thinking of life or quality life for those future patients of head and neck cancer and your bragging about being on numberous other boards like this one those sicknesses either. Just like I said Money Rules even over life.
0 · Reply
MrAJax
MrAJax Oct. 25 at 6:47 PM
$CVM Geert & Saudi Arabia you are on the clock!!!! Time is running out this 60 day kicked can, will only go so far.
0 · Reply
cruiser24
cruiser24 Oct. 25 at 6:20 PM
@BioAmerica $CVM BULLISH WELL you keep posting to me expect an answer. You seem to pretend to have a problem and I’ve told you how to handle it. But NOOO you prefer to be cantankerous and act like you are some kind of boss. You might talk to your husband with a dog whistle but you are whistling in the wind here. GLTA-BULLS POAY-bears Just another day closer.
0 · Reply
BioAmerica
BioAmerica Oct. 25 at 4:24 PM
$CVM Had a little time this morning, and had a discussion with a long who has only been around a couple years. He asked me where I get all the information about all the past deals with the company. He was very interested in the 2014-2018 time frame. I found this old link to the an old annual report. It tries to explain the HALT of the trial: https://www.sec.gov/Archives/edgar/data/725363/000165495417003711/cvm_ars.pdf Start on about page 4. It explains a lot, for those who were not around back then. If have more time, you can go to the below site and read the annual reports for the next couple years. You might see an interesting change as each year goes on. https://www.annualreports.com/Company/cel-sci-corp You might have to click on "Show 10 older reports" to get to the 2017, 2018, 2019 reports. Some interesting stuff in there.
1 · Reply
cruiser24
cruiser24 Oct. 25 at 2:54 PM
$CVM BULLISH Had to take a bathroom break. That prune juice is really working. Get up out of there BG and get to work. GLTA-BULLS POAY-bears
0 · Reply
cruiser24
cruiser24 Oct. 25 at 2:44 PM
$CVM BULLISH Rich. Very rich. You make a post to @cruiser24 and then get your panties in a wad acting offended because you are answered by me. I reported you as well. Don’t start no crap won’t be no crap. Take your meds. GLTA-BULLS POAY-bears Block me and quit posting me dufus.
1 · Reply
cruiser24
cruiser24 Oct. 25 at 11:29 AM
$CVM BULLISH You won’t get any argument here. I concur. You are definitely the Spam Champion of the World. Did you get a big ole belt when you won? GLTA-BULLS POAY-bears Another day closer.
0 · Reply
prophet777
prophet777 Oct. 25 at 9:24 AM
$CVM hey what happened to our immxbiopharma/you seem angry boy… he was amusing…
0 · Reply
cruiser24
cruiser24 Oct. 24 at 10:13 PM
$CVM BULLISH Standards huh? SMH So who is the moderators of this board?
0 · Reply
cruiser24
cruiser24 Oct. 24 at 7:06 PM
$CVM News can present itself any day stocks are trading M-F. I changed my portrait so I could talk to BioGLoveMe face to face . GLTA-BULLS POAY-bears Any time now.
0 · Reply
cruiser24
cruiser24 Oct. 24 at 6:57 PM
$CVM Who has power to prevent post from showing on this board?
1 · Reply
cruiser24
cruiser24 Oct. 24 at 4:45 PM
$CVM Would be nice after hours to hear the explosion.
1 · Reply
cruiser24
cruiser24 Oct. 24 at 4:44 PM
$CVM Tick Tok
1 · Reply
cruiser24
cruiser24 Oct. 24 at 4:43 PM
$CVM
1 · Reply
cruiser24
cruiser24 Oct. 24 at 4:37 PM
$CVM
1 · Reply
Thebullrun
Thebullrun Oct. 24 at 3:34 PM
$CVM interesting!
1 · Reply
Setura
Setura Oct. 24 at 3:21 PM
$CVM Bought another 200 :) Have 936 Shares now.
0 · Reply
Johnyd
Johnyd Oct. 24 at 2:16 PM
$CVM wiilie the T hi rollin fatasy!
0 · Reply
Johnyd
Johnyd Oct. 24 at 2:09 PM
$CVM GERT MORNIN! GERT MORNIN! "luigi"is callin?
0 · Reply
Mey636363
Mey636363 Oct. 24 at 8:12 AM
$CVM now it's time to move,
1 · Reply
Jamesse
Jamesse Oct. 24 at 1:06 AM
$CVM wtf 凸
0 · Reply
cruiser24
cruiser24 Oct. 23 at 11:54 PM
$CVM BULLISH First I never commented on the bags but only to his remark calling me the biggest bagger. Spammer. Secondly you seriously need to reach out to professionals in neurology to address your loss of memor, as I have posted tine and again I do not use a computer. So if I were in a nursing home to which you sound like you are a short time being admitted, having limited time on a computer would not save you from me showing your post as spam.
0 · Reply